BioAtla
BCAB
82 hedge funds and large institutions have $87.2M invested in BioAtla in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 14 closing their positions.
3,056% more call options, than puts
Call options by funds: $505K | Put options by funds: $16K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
22% more capital invested
Capital invested by funds: $71.3M → $87.2M (+$16M)
4% more funds holding
Funds holding: 79 → 82 (+3)
0.15% less ownership
Funds ownership: 1.21% → 1.06% (-0.15%)
21% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.63M |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$821K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$408K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$331K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$296K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.76M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.61M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.74M |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$1.74M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.48M |
BCAB Hedge Fund Activity: Q1 2024 in Review
82 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q1 2024, worth a combined $87.2M — up 22% from $71.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BCAB positions and 14 closed out — a net gain of 4 holders — while 23 added to existing stakes and 29 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.63M. The largest seller was Morgan Stanley, cutting an estimated $4.76M.
- 82 institutional investors held BioAtla (BCAB) as of Q1 2024, up from 79 in Q4 2023.
- Funds reported $87.2M of BioAtla stock for Q1 2024, up 22% quarter-over-quarter.
- 18 funds opened new BioAtla positions in Q1 2024 and 14 closed out, a net change of +4 holders.
- The largest BioAtla buyer in Q1 2024 was Millennium Management, an estimated $1.63M added.
- The largest BioAtla seller in Q1 2024 was Morgan Stanley, an estimated $4.76M sold.
Based on aggregated 13F filings for Q1 2024.